BRCA2 and familial pancreatic carcinoma: Similar results have been reported in studies focusing on the role of KRAS gene in tumor development [12], and research on inactivation of the DNA maintenance genes, including BRCA1, BRCA2, and PALB2, demonstrated that patients with pancreatic cancer with defective DNA maintenance genes responded better to platinum-based chemotherapy [13].